Table 3.
Targeted AEs reported by ≥10 % of all patients
| Injection administered by | |||||
|---|---|---|---|---|---|
| Patient (n = 26) | Partner (n = 41) | HCP (n = 58) | Combination/other (n = 41) | All patients (n = 166) | |
| Number of patients with ≥1 targeted AE (n, %) | 15 (58) | 23 (56) | 30 (52) | 23 (56) | 91 (55) |
| Targeted AEs | |||||
| Arthralgia | 4 (15) | 9 (22) | 17 (29) | 6 (15) | 36 (22) |
| Headache | 8 (31) | 10 (25) | 9 (16) | 9 (22) | 36 (22) |
| Diarrhea | 1 (4) | 12 (29) | 8 (14) | 11 (27) | 32 (19) |
| Abdominal pain | 2 (8) | 10 (24) | 10 (17) | 9 (22) | 31 (19) |
| Nausea | 0 | 10 (24) | 9 (16) | 5 (12) | 24 (15) |
| Constipation | 3 (12) | 4 (10) | 8 (14) | 7 (17) | 22 (13) |
| Flatulence | 2 (8) | 7 (17) | 4 (7) | 8 (20) | 21 (13) |
| Injection site reaction | 5 (19) | 1 (2) | 4 (7) | 3 (7) | 13 (8) |
AEs adverse events, HCP healthcare provider